Today: 19 May 2026
Browse Category

NYSE:CVS 29 October 2025 - 11 December 2025

CVS Health Stock Surges on 2025–2026 Guidance: Key News, Forecasts and Analysis Since November 21, 2025

CVS Health Stock Surges on 2025–2026 Guidance: Key News, Forecasts and Analysis Since November 21, 2025

CVS Health shares have surged about 70–80% year-to-date in 2025, trading near $80.6 and lifting the company’s market value to just under $100 billion. Q3 revenue rose nearly 8% to $102.9 billion, but a $5.7 billion goodwill impairment drove a GAAP net loss of almost $4 billion. CEO David Joyner will become board chair. CVS reached a $37.8 million federal settlement over insulin pen dispensing.
11 December 2025
··
CVS Health (CVS) Stock Soars in 2025 on New Guidance, AI Push and Clinic Reset – Is the Turnaround Finally Real?

CVS Health (CVS) Stock Soars in 2025 on New Guidance, AI Push and Clinic Reset – Is the Turnaround Finally Real?

CVS Health raised its 2025–2026 profit outlook and launched an AI-driven engagement platform at its Investor Day in Hartford, sending shares up 2% to around $78 on December 10. The stock has surged nearly 80% year to date. CVS now expects at least $400 billion in 2025 revenue and adjusted EPS of $6.60–$6.70, above prior guidance. Management projects mid-teens adjusted EPS growth through 2028.
10 December 2025
··
CVS Stock Outlook: Fresh Legal Headlines, Analyst Upgrades and 2026 Forecast (December 6, 2025)

CVS Stock Outlook: Fresh Legal Headlines, Analyst Upgrades and 2026 Forecast (December 6, 2025)

CVS Health shares traded near $75.60 on December 6, 2025, after a strong rally and a series of legal settlements, including a $37.8 million insulin pen case and an $18.2 million False Claims Act settlement. A federal judge also ordered CVS Caremark to pay nearly $290 million for Medicare overcharges. Management raised 2025 profit guidance and projected double-digit earnings growth for 2026.
6 December 2025
CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

CVS Health shares fell 1.9% to $77.62 on December 2, 2025, underperforming the S&P 500 and healthcare peers after news of a $37.76 million federal settlement over insulin-pen billing. Trading volume topped 7.7 million shares, above average. The stock remains up about 75–80% for the year but sits roughly 8–9% below its late October high. CVS did not admit liability in the settlement.
3 December 2025
···
CVS Health Stock in December 2025: Price, Forecast, Dividend and Whether the Rally Still Has Room to Run

CVS Health Stock in December 2025: Price, Forecast, Dividend and Whether the Rally Still Has Room to Run

CVS Health shares closed at $79.10 on December 1, 2025, down 1.6% and about 7% below their 52-week high. The stock is up nearly 79% year-to-date. Q3 revenue rose 7.8% to $102.9 billion, with adjusted EPS of $1.60 but a GAAP loss per share of –$3.13 due to a $5.7 billion non-cash goodwill impairment. CVS’s trailing P/E ratio spiked above 200 from the one-time charge.
2 December 2025
··
CVS Health Stock Today (NYSE: CVS): Institutional Buying, New Board Chair and Q3 Shock Shape Outlook – November 23, 2025

CVS Health Stock Today (NYSE: CVS): Institutional Buying, New Board Chair and Q3 Shock Shape Outlook – November 23, 2025

CVS Health stock closed Friday at $78.03, up nearly 80% from its 52-week low but still below its high. New 13F filings released Sunday show major institutions, including Handelsbanken Fonder AB and DNB Asset Management AS, increased their stakes in Q2. Institutional investors now hold over 80% of CVS shares. The company is also restructuring its primary care and PBM operations.
23 November 2025
·
Thanksgiving 2025 Store Hours: Is Kroger Open? H‑E‑B Hours, Louisville Malls and Which Stores Are Closed

Thanksgiving 2025 Store Hours: Is Kroger Open? H‑E‑B Hours, Louisville Malls and Which Stores Are Closed

Kroger stores will open on Thanksgiving 2025 with reduced hours, closing by mid-afternoon; pharmacies remain closed. H-E-B will operate 6 a.m. to noon. Louisville malls and most national chains, including Walmart, Target, and Costco, will be closed. Meijer, Food Lion, Whole Foods, and several Albertsons stores will open but close early.
21 November 2025
··········
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

WeightWatchers plans to offer Novo Nordisk’s oral Wegovy in the U.S. after its expected 2026 launch. Sandoz says unbranded Ozempic could reach Canada by June 2026, intensifying price competition. CVS dropped Lilly’s Zepbound from its preferred list, keeping Wegovy, prompting Lilly to move employees off CVS plans. Novo Nordisk shares traded at $49.76 late Wednesday, up slightly.
12 November 2025
·····
1 2 3

Stock Market Today

  • Euronext Reports 5.8% Rise in FX Trading Revenue in Q1 2026
    May 19, 2026, 12:33 PM EDT. Euronext, a European capital market infrastructure operator, reported a 5.8% year-on-year increase in foreign exchange (FX) trading revenue for the first quarter of 2026. The growth highlights steady demand in FX markets despite volatile economic conditions. Euronext published its quarterly results showing resilience in trading operations, underlying its role in the European financial ecosystem.

Latest articles

Why Constellation Software Stock Is Jumping While Canada’s Market Slips

Why Constellation Software Stock Is Jumping While Canada’s Market Slips

19 May 2026
Toronto, May 19, 2026, 12:05 (EDT) Constellation Software shares jumped on Tuesday, rising 9.5% to C$2,860.21 at 11:40 a.m. in Toronto, as investors bought back into one of Canada’s biggest software names while the broader S&P/TSX composite edged lower. Google Finance showed the stock opening at C$2,625.00 and touching C$2,880.35 intraday. (Google) The move matters because trading resumed after Monday’s Victoria Day closure, giving investors a fresh chance to react to last week’s earnings, analyst calls and the broader debate over whether artificial intelligence will weaken or help the company’s portfolio of niche software businesses. TMX said Canadian exchanges would
InMed Soars 100% on $290M Migraine Deal

InMed Soars 100% on $290M Migraine Deal

19 May 2026
InMed Pharmaceuticals shares jumped 108.6% to $1.42 after agreeing to merge with Mentari Therapeutics in an all-stock deal, shifting focus to migraine prevention. The combined company will operate as Mentari, backed by a $290 million private placement, with InMed shareholders owning about 1.51%. Nearly 69.6 million shares traded, and InMed’s market value reached $5.7 million.
Anthropic Brings on OpenAI Co-Founder Andrej Karpathy

Anthropic Brings on OpenAI Co-Founder Andrej Karpathy

19 May 2026
Anthropic has hired Andrej Karpathy, a founding OpenAI member and former Tesla AI executive, to join its pre-training team. Karpathy will work under Nick Joseph and lead efforts to use Claude to speed pre-training research. He starts this week. Anthropic has also added Chris Rohlf, a cybersecurity specialist, to its frontier red team.

Popular

Go toTop